AP2015008504A0 - Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms - Google Patents

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms

Info

Publication number
AP2015008504A0
AP2015008504A0 AP2015008504A AP2015008504A AP2015008504A0 AP 2015008504 A0 AP2015008504 A0 AP 2015008504A0 AP 2015008504 A AP2015008504 A AP 2015008504A AP 2015008504 A AP2015008504 A AP 2015008504A AP 2015008504 A0 AP2015008504 A0 AP 2015008504A0
Authority
AP
ARIPO
Prior art keywords
myeloprolifarative
neoplasms
treatment
myeloproliferative disorders
telomerase inhibitors
Prior art date
Application number
AP2015008504A
Other languages
English (en)
Inventor
Stephen Kelsey
Monic J Stuart
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of AP2015008504A0 publication Critical patent/AP2015008504A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AP2015008504A 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms AP2015008504A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
AP2015008504A0 true AP2015008504A0 (en) 2015-06-30

Family

ID=50883867

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008504A AP2015008504A0 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms

Country Status (37)

Country Link
EP (3) EP2928477B1 (de)
JP (6) JP6433911B2 (de)
KR (4) KR102662590B1 (de)
CN (2) CN111617252A (de)
AP (1) AP2015008504A0 (de)
AU (4) AU2013356533B2 (de)
BR (1) BR112015013260A2 (de)
CA (2) CA3188494A1 (de)
CL (2) CL2015001530A1 (de)
CY (3) CY1122169T1 (de)
DK (3) DK3456333T3 (de)
EA (1) EA032973B1 (de)
ES (3) ES2982897T3 (de)
FI (2) FI3646876T3 (de)
FR (1) FR25C1016I2 (de)
HK (1) HK1210940A1 (de)
HR (3) HRP20191784T1 (de)
HU (4) HUE045098T2 (de)
IL (3) IL317233A (de)
LT (4) LT3456333T (de)
MA (2) MA38193B1 (de)
ME (1) ME03538B (de)
MX (3) MX372753B (de)
MY (2) MY180634A (de)
NL (1) NL301326I2 (de)
NZ (1) NZ708920A (de)
PH (2) PH12019501008A1 (de)
PL (3) PL2928477T3 (de)
PT (3) PT3456333T (de)
RS (2) RS60401B1 (de)
SG (3) SG11201504383TA (de)
SI (3) SI2928477T1 (de)
SM (2) SMT201900567T1 (de)
TN (1) TN2015000249A1 (de)
UA (3) UA128370C2 (de)
WO (1) WO2014088785A1 (de)
ZA (3) ZA201504124B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02933B (de) 2004-07-02 2018-04-20 Geron Corp Synthese geschützter 3'-aminonukleosidmonomere
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
PL3065828T3 (pl) 2013-11-06 2019-06-28 Mayo Foundation For Medical Education And Research Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych
AU2016250576C1 (en) 2015-04-23 2021-05-06 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
EP3318276A1 (de) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Zusammensetzungen aus einem telomerase-hemmer und einem bcl-2-hemmer zur behandlung von blutkrebs
KR102867725B1 (ko) * 2017-07-28 2025-10-13 제론 코포레이션 골수형성이상 증후군의 치료 방법
IL308399B2 (en) * 2018-04-30 2025-08-01 Kartos Therapeutics Inc Methods of treating cancer
CN112804994A (zh) * 2018-05-25 2021-05-14 卡托斯医疗公司 治疗骨髓增殖性肿瘤的方法
US20200063214A1 (en) * 2018-07-31 2020-02-27 Geron Corporation Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
UA130012C2 (uk) 2018-11-29 2025-10-15 Джерон Корпорейшн Спосіб лікування мієлодиспластичного синдрому
CN115666588A (zh) 2019-11-04 2023-01-31 美国杰龙生物医药公司 Janus激酶抑制剂和端粒酶抑制剂用于治疗骨髓增殖性肿瘤的用途
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
JP2023534295A (ja) * 2020-07-17 2023-08-08 ジェロン・コーポレーション 皮下テロメラーゼ阻害剤組成物及びそれらを使用するための方法
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法
WO2024259369A1 (en) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
EP1606302A4 (de) * 2003-01-31 2009-02-18 Jessie L S Au Verfahren und zusammensetzungen zur verwendung von suramin, pentosanpolysulfat, telomerase-antisense und telomerase-hemmern
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
CN100393209C (zh) 2003-09-09 2008-06-11 杰龙公司 用于端粒酶抑制的改性寡核苷酸
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
ME02933B (de) 2004-07-02 2018-04-20 Geron Corp Synthese geschützter 3'-aminonukleosidmonomere
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
EP1876893B1 (de) 2005-04-15 2012-04-11 Geron Corporation Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
SI2898887T1 (sl) 2006-10-30 2019-01-31 Geron Corporation Kombinirani telomerazni inhibitor in gemcitabin za zdravljenje raka
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
MY180634A (en) 2020-12-03
WO2014088785A8 (en) 2015-07-16
CA3188494A1 (en) 2014-06-12
PH12015501282A1 (en) 2015-08-24
RS59363B1 (sr) 2019-11-29
EA201590878A1 (ru) 2016-04-29
LT3646876T (lt) 2024-05-10
IL280144B1 (en) 2025-01-01
CY2025015I1 (el) 2026-02-25
ES2789176T3 (es) 2020-10-26
FI3646876T3 (fi) 2024-05-14
CY2025015I2 (el) 2026-02-25
UA126015C2 (uk) 2022-08-03
SG10201802926XA (en) 2018-05-30
PH12015501282B1 (en) 2015-08-24
EP2928477A1 (de) 2015-10-14
DK3456333T3 (da) 2020-05-18
DK3646876T3 (da) 2024-05-06
EP3456333A1 (de) 2019-03-20
SMT201900567T1 (it) 2019-11-13
MA38193B1 (fr) 2018-12-31
IL280144B2 (en) 2025-05-01
JP2016504307A (ja) 2016-02-12
HRP20191784T1 (hr) 2019-12-27
IL280144A (en) 2021-03-01
MY200076A (en) 2023-12-06
CN104936602A (zh) 2015-09-23
ES2744790T3 (es) 2020-02-26
HUE049858T2 (hu) 2020-11-30
WO2014088785A1 (en) 2014-06-12
MA38193A1 (fr) 2017-12-29
KR20150091130A (ko) 2015-08-07
JP2020041001A (ja) 2020-03-19
NL301326I2 (nl) 2025-07-31
SMT202000328T1 (it) 2020-07-08
ES2982897T3 (es) 2024-10-18
CL2015001530A1 (es) 2016-03-28
PT3456333T (pt) 2020-06-01
ME03538B (de) 2020-07-20
IL239266B (en) 2019-11-28
HK1210940A1 (zh) 2016-05-13
FIC20250019I1 (fi) 2025-05-07
KR102294819B1 (ko) 2021-09-01
JP2022050537A (ja) 2022-03-30
LT3456333T (lt) 2020-06-25
AU2024203138A1 (en) 2024-07-25
HUS2500019I1 (hu) 2025-05-28
LTPA2025517I1 (de) 2025-05-26
AU2020267142B2 (en) 2024-05-16
MX2015007169A (es) 2016-03-31
HRP20240624T1 (hr) 2024-08-02
LT2928477T (lt) 2019-10-10
PH12019501008A1 (en) 2022-11-14
EP3456333B1 (de) 2020-04-01
CA2892907C (en) 2023-03-21
PT3646876T (pt) 2024-05-15
UA128370C2 (uk) 2024-06-26
KR102662590B1 (ko) 2024-05-03
MX372753B (es) 2020-06-26
ZA202108991B (en) 2023-05-31
AU2020267142A1 (en) 2020-12-03
MX2020003276A (es) 2020-07-20
KR20230028590A (ko) 2023-02-28
PL3456333T3 (pl) 2020-09-21
NZ708920A (en) 2020-08-28
AU2013356533B2 (en) 2018-09-27
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
IL317233A (en) 2025-01-01
NZ748134A (en) 2020-10-30
JP6998191B2 (ja) 2022-02-04
SI3456333T1 (sl) 2020-10-30
JP7288098B2 (ja) 2023-06-06
CY1123206T1 (el) 2021-10-29
AU2020267142C1 (en) 2024-08-08
KR20210107906A (ko) 2021-09-01
IL239266A0 (en) 2015-07-30
ZA202212327B (en) 2025-03-26
PL2928477T3 (pl) 2020-03-31
CL2017002156A1 (es) 2018-05-04
SI3646876T1 (sl) 2024-07-31
DK2928477T3 (da) 2019-10-07
EP3646876A1 (de) 2020-05-06
UA117116C2 (uk) 2018-06-25
AU2018282364A1 (en) 2019-05-23
BR112015013260A2 (pt) 2018-02-06
PT2928477T (pt) 2019-10-25
HUE066402T2 (hu) 2024-07-28
FR25C1016I2 (fr) 2026-04-17
EP2928477B1 (de) 2019-07-24
EP3646876B1 (de) 2024-02-14
MA45504B1 (fr) 2021-10-29
JP6433911B2 (ja) 2018-12-05
KR20250114449A (ko) 2025-07-29
MX2022015437A (es) 2023-01-11
CN111617252A (zh) 2020-09-04
EP2928477A4 (de) 2016-09-21
EA032973B1 (ru) 2019-08-30
CA2892907A1 (en) 2014-06-12
SG10202103341SA (en) 2021-05-28
AU2013356533A1 (en) 2014-06-12
SG11201504383TA (en) 2015-07-30
ZA201504124B (en) 2017-05-31
PL3646876T3 (pl) 2024-07-22
CN104936602B (zh) 2020-07-17
CY1122169T1 (el) 2020-11-25
JP2018035196A (ja) 2018-03-08
SI2928477T1 (sl) 2019-11-29
RS60401B1 (sr) 2020-07-31
MA45504A1 (fr) 2020-05-29
EP3456333B8 (de) 2020-05-13
JP2025109842A (ja) 2025-07-25
HK1212226A1 (en) 2016-06-10
TN2015000249A1 (en) 2016-10-03
FR25C1016I1 (fr) 2025-06-20
JP2022179684A (ja) 2022-12-02

Similar Documents

Publication Publication Date Title
ZA202108991B (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
IL283943B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
ZA201607980B (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP2890440A4 (de) Vorrichtungen und verfahren zur behandlung von gefässerkrankungen
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL234841A0 (en) Administration forms of halofuginone and methods of use
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
PL2846805T3 (pl) Leczenie uzależnień i zaburzeń kontroli impulsów za pomocą inhibitorów PDE7
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
HUE043518T2 (hu) Függõség és impulzuskontroll zavarok kezelése PDE-7-inhibitorok alkalmazásával